Literature DB >> 2442936

Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.

L Molin, K Thomsen, G Volden, A Aronsson, H Hammar, L Hellbe, G L Wantzin, G Roupe.   

Abstract

Thirty-nine patients with mycosis fungoides in various stages or Sézary syndrome were treated with isotretinoin and 29 with etretinate as single drug therapy. Complete remission within 2 months was obtained with isotretinoin in 8 cases (21%) and partial remission in another 15 cases (38%). Etretinate induced complete remission in 5 cases (21%) and partial remission in 11 (46%). Only 1 case with Sézary syndrome went into partial remission. The first sign of remission occurred in 2 to 4 weeks. During continued treatment remissions could not always be maintained. Isotretinoin and etretinate were considered to be of equal potency in the treatment of mycosis fungoides.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442936

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  5 in total

1.  Use of oral isotretinoin in the management of rosacea.

Authors:  Hyunhee Park; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

Review 2.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

3.  Cost of early-stage mycosis fungoides treatments in Spain.

Authors:  Pablo Luis Ortiz-Romero; Octavio Servitje; María Teresa Estrach; Rosa María Izu-Belloso; Ricardo Fernández-de-Misa; Fernando Gallardo; Noemí López-Martínez; Alejandro Pérez-Mitru
Journal:  Clinicoecon Outcomes Res       Date:  2020-02-12

4.  Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions.

Authors:  Sherman Chu; Lauren Michelle; Chloe Ekelem; Calvin T Sung; Nathan Rojek; Natasha A Mesinkovska
Journal:  Arch Dermatol Res       Date:  2020-11-05       Impact factor: 3.017

Review 5.  Oral retinoids and rexinoids in cutaneous T-cell lymphomas.

Authors:  Małgorzata Sokołowska-Wojdyło; Hanna Lugowska-Umer; Agata Maciejewska-Radomska
Journal:  Postepy Dermatol Alergol       Date:  2013-02-20       Impact factor: 1.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.